ĐẶC ĐIỂM BỆNH NHÂN VIÊM CỘT SỐNG DÍNH KHỚP ĐIỀU TRỊ NỘI TRÚ TẠI TRUNG TÂM CƠ XƯƠNG KHỚP BỆNH VIỆN BẠCH MAI NĂM 2021

Abstract

Objectives: To describe the diagnosis and treatment characteristics of patients with ankylosing spondylitis (AS) at the Centre for Rheumatology of Bach Mai Hospital. Subjects and methods: This was a retrospective cross-sectional study that reviewed 218 patients with AS including 633 medical records (courses of treatment) from January 2021 to December 2021. Results: A total of 218 patients were included with a male predisposition (male-to-female ratio 4.9/1); the mean age was 28.8 ± 10.8 years; the mean disease duration was 4.0 ± 4.4 years. Both axial and peripheral AS manifestations were noted in 77.6% of patients, while solely axial or peripheral manifestations group accounted for 19.7% and 2.7% respectively. On average, each patient has 2.9 courses of treatment in 2021, of which the proportion of patients with more than 5 courses per year for only 10.1%. Among 218 patients, a total 173 patients of administered biological DMARDs (79.4%) were observed, including anti- TNF group (adalimumab, infliximab, golimumab) (59.6%) vs the anti-interleukin IL-17A group (secukinumab) (40.4%). Conclusion: Ankylosing spondylitis was more prevalent in young males, and the most common type was the combined axial and peripheral AS. The courses of treatment per year were low, and the proportion of patients treated with biological DMARDs accounts for the higher percentage, especially anti-TNF drugs.